tiprankstipranks
ONO Pharmaceutical Co Ltd (OPHLF)
OTHER OTC:OPHLF
US Market
OPHLF
ONO Pharmaceutical Co
RESEARCH TOOLSreports

ONO Pharmaceutical Co (OPHLF) Stock Forecast & Price Target

21 Followers
See the Price Targets and Ratings of:

OPHLF Analyst Ratings

Moderate Sell
2Ratings
Moderate Sell
0 Buy
1 Hold
1 Sell
Based on 2 analysts giving stock ratings to
ONO
Pharmaceutical Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OPHLF Stock 12 Month Forecast

Average Price Target

$13.73
▼(-1.91% Downside)
Based on 2 Wall Street analysts offering 12 month price targets for ONO Pharmaceutical Co in the last 3 months. The average price target is $13.73 with a high forecast of $15.61 and a low forecast of $11.86. The average price target represents a -1.91% change from the last price of $14.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","12":"$12","17":"$17","9.5":"$9.5","14.5":"$14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15.605,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.7324,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.8598,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.86</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,9.5,12,14.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.55,14.631153846153847,14.712307692307693,14.793461538461539,14.874615384615385,14.955769230769231,15.036923076923078,15.118076923076924,15.19923076923077,15.280384615384616,15.361538461538462,15.442692307692308,15.523846153846154,{"y":15.605,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.55,14.487107692307694,14.424215384615385,14.361323076923078,14.29843076923077,14.235538461538463,14.172646153846154,14.109753846153847,14.046861538461538,13.983969230769231,13.921076923076923,13.858184615384616,13.795292307692307,{"y":13.7324,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.55,14.343061538461539,14.136123076923077,13.929184615384615,13.722246153846154,13.515307692307692,13.30836923076923,13.10143076923077,12.894492307692309,12.687553846153847,12.480615384615385,12.273676923076923,12.066738461538462,{"y":11.8598,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.927,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.925,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.364,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.689,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.165,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.982,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":13.043,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.639,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.948,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.402,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.55,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.8,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.55,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$15.61Average Price Target$13.73Lowest Price Target$11.86
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on OPHLF
Stephen Barker
Jefferies
Jefferies
$15.61
Hold
11.46%
Upside
Reiterated
05/29/26
Analysts Are Neutral on These Healthcare Stocks: CSL (CMXHF), ONO Pharmaceutical Co (OPHLF)
Goldman Sachs Analyst forecast on OPHLF
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$9.36→$11.86
Sell
-15.29%
Downside
Reiterated
04/15/26
Goldman Sachs Remains a Sell on ONO Pharmaceutical Co (OPHLF)
Citi Analyst forecast on OPHLF
Hidemaru Yamaguchi
Citi
Citi
$10.61→$10.92
Hold
-21.97%
Downside
Reiterated
08/28/25
ONO Pharmaceutical Co (OPHLF) Gets a Hold from Citi
J.P. Morgan Analyst forecast on OPHLF
Seiji Wakao
J.P. Morgan
J.P. Morgan
$8.11
Sell
-42.04%
Downside
Reiterated
07/15/25
J.P. Morgan Sticks to Its Sell Rating for ONO Pharmaceutical Co (OPHLF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on OPHLF
Stephen Barker
Jefferies
Jefferies
$15.61
Hold
11.46%
Upside
Reiterated
05/29/26
Analysts Are Neutral on These Healthcare Stocks: CSL (CMXHF), ONO Pharmaceutical Co (OPHLF)
Goldman Sachs Analyst forecast on OPHLF
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
$9.36→$11.86
Sell
-15.29%
Downside
Reiterated
04/15/26
Goldman Sachs Remains a Sell on ONO Pharmaceutical Co (OPHLF)
Citi Analyst forecast on OPHLF
Hidemaru Yamaguchi
Citi
Citi
$10.61→$10.92
Hold
-21.97%
Downside
Reiterated
08/28/25
ONO Pharmaceutical Co (OPHLF) Gets a Hold from Citi
J.P. Morgan Analyst forecast on OPHLF
Seiji Wakao
J.P. Morgan
J.P. Morgan
$8.11
Sell
-42.04%
Downside
Reiterated
07/15/25
J.P. Morgan Sticks to Its Sell Rating for ONO Pharmaceutical Co (OPHLF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ONO Pharmaceutical Co

3 Months
OpenAI Drug Manufacturers - GeneralTipRanks - OpenAI
Success Rate
1/2 ratings generated profit
50%
Average Return
+3.10%
Copying OpenAI Drug Manufacturers - General's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +3.10% per trade.
1 Year
OpenAI Drug Manufacturers - GeneralTipRanks - OpenAI
Success Rate
2/2 ratings generated profit
100%
Average Return
+15.10%
Copying OpenAI Drug Manufacturers - General's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.10% per trade.
2 Years
OpenAI Drug Manufacturers - GeneralTipRanks - OpenAI
Success Rate
2/2 ratings generated profit
100%
Average Return
+15.10%
Copying OpenAI Drug Manufacturers - General's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +15.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OPHLF Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
0
0
0
1
1
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
0
0
1
2
2
In the current month, OPHLF has received 0 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. OPHLF average Analyst price target in the past 3 months is 13.73.
Each month's total comprises the sum of three months' worth of ratings.

OPHLF Financial Forecast

OPHLF Earnings Forecast

Next quarter’s earnings estimate for OPHLF is $0.21 with a range of $0.16 to $0.28. The previous quarter’s EPS was $0.01. OPHLF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year OPHLF has Performed in-line its overall industry.
Next quarter’s earnings estimate for OPHLF is $0.21 with a range of $0.16 to $0.28. The previous quarter’s EPS was $0.01. OPHLF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year OPHLF has Performed in-line its overall industry.

OPHLF Sales Forecast

Next quarter’s sales forecast for OPHLF is $665.41M with a range of $641.63M to $700.30M. The previous quarter’s sales results were $740.52M. OPHLF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year OPHLF has Performed in-line its overall industry.
Next quarter’s sales forecast for OPHLF is $665.41M with a range of $641.63M to $700.30M. The previous quarter’s sales results were $740.52M. OPHLF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year OPHLF has Performed in-line its overall industry.

OPHLF Stock Forecast FAQ

What is OPHLF’s average 12-month price target, according to analysts?
Based on analyst ratings, ONO Pharmaceutical Co Ltd’s 12-month average price target is 13.73.
    What is OPHLF’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for OPHLF, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is OPHLF a Buy, Sell or Hold?
        ONO Pharmaceutical Co Ltd has a consensus rating of Moderate Sell which is based on 0 buy ratings, 1 hold ratings and 1 sell ratings.
          What is ONO Pharmaceutical Co Ltd’s price target?
          The average price target for ONO Pharmaceutical Co Ltd is 13.73. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $15.61 ,the lowest forecast is $11.86. The average price target represents -1.91% Decrease from the current price of $14.
            What do analysts say about ONO Pharmaceutical Co Ltd?
            ONO Pharmaceutical Co Ltd’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 2 Wall Streets Analysts.
              How can I buy shares of OPHLF?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.